Saif Passant Sayed, Okasha Mohamed Gaber, Mahmoud Hatem, Samir Asmaa, Abdelmonagy Ibrahim Mohamed
Department of Ophthalmology, Misr University for Science and Technology, Giza, Egypt.
Department of Ophthalmology, Faculty of Medicine, Al-Azhar University for Boys, Cairo, Egypt.
Sci Rep. 2025 Aug 27;15(1):31553. doi: 10.1038/s41598-025-14330-3.
To evaluate endothelial cell density (ECD) and corneal biomechanical changes following implantation of Veriflex and Implantable Collamer Lens (ICL) phakic intraocular lenses (pIOLs) over a 12-month period. Sixty patients (117 eyes) were included in this prospective comparative study. 58 eyes underwent implantation with the Veriflex lens (Group I), while 59 eyes received the ICL (Group II). Preoperative and postoperative ECD and corneal biomechanical values were assessed using specular microscopy and Corvis St at baseline, 6 months, and 1 year. Endothelial cell loss percentages and corneal biomechanical changes were calculated and compared between the 2 groups. Preoperatively, the mean ECD was 2683.4 ± 340.6 cells/mm in Group I and 2732 ± 322.8 cells/mm in Group II (P = 0.718). At 1 year, Group I exhibited a significantly greater reduction in ECD compared to Group II (P = 0.021), indicating higher endothelial cell loss with Veriflex. The mean endothelial cell loss at 12 months was 5.4% (145.7 ± 62.8 cells/mm) in Group I compared to 1.53% (42 ± 17.3 cells/mm) in Group II (P < 0.001). The Veriflex group showed greater corneal biomechanical changes, with a deformation amplitude (DA) increase to 1.15 ± 0.11 mm and a highest concavity time (HCT) of 17.2 ± 1.1 ms, while the ICL group demonstrated more stable biomechanics, with a DA of 1.09 ± 0.09 mm and an HCT of 16.6 ± 1.0 ms at one year postoperatively. Both Veriflex and ICL pIOLs resulted in a decrease in ECD over one year, with Veriflex showing a significantly higher rate of endothelial cell loss. These findings suggest that ICL may be a safer option for long-term endothelial preservation. Long-term studies are required to assess the continued impact of both lenses on corneal endothelial health.
评估Veriflex和可植入式胶原晶状体（ICL）有晶状体眼人工晶状体（pIOL）植入后12个月内的内皮细胞密度（ECD）和角膜生物力学变化。本前瞻性对照研究纳入了60例患者（117只眼）。58只眼植入了Veriflex晶状体（I组），而59只眼植入了ICL（II组）。在基线、6个月和1年时，使用镜面显微镜和Corvis St评估术前和术后的ECD和角膜生物力学值。计算并比较两组的内皮细胞丢失百分比和角膜生物力学变化。术前，I组的平均ECD为2683.4±340.6个细胞/mm²，II组为2732±322.8个细胞/mm²（P = 0.718）。1年时，与II组相比，I组的ECD下降明显更大（P = 0.021），表明Veriflex导致的内皮细胞丢失更高。I组12个月时的平均内皮细胞丢失率为5.4%（145.7±62.8个细胞/mm²），而II组为1.53%（42±17.3个细胞/mm²）（P < 0.001）。Veriflex组显示出更大的角膜生物力学变化，变形幅度（DA）增加到1.15±0.11mm，最高凹陷时间（HCT）为17.2±1.1ms，而ICL组在术后1年表现出更稳定的生物力学，DA为1.09±0.09mm，HCT为16.6±1.0ms。Veriflex和ICL pIOL在1年内均导致ECD下降，Veriflex的内皮细胞丢失率明显更高。这些发现表明，ICL可能是长期保存内皮细胞的更安全选择。需要进行长期研究来评估两种晶状体对角膜内皮健康的持续影响。
